Healthcare Equipment and Supplies
Company Overview of Bioness Inc.
Bioness Inc. designs, develops, and distributes medical devices for people with stroke, multiple sclerosis, traumatic brain injury, cerebral palsy, and spinal cord injury. It offers L300, a foot drop system for people with various neurological conditions; L300 Plus for foot drop and thigh weakness, which delivers programmed, low-level electrical stimulation to activate the nerves controlling the muscles of the leg; H200, a wireless hand rehabilitation system for reaching, grasping, opening, and closing the hand; and StimRouter, an implantable neuromodulation device designed to treat intractable pain of peripheral nerve origin. The company also offers StimRouter, an implantable neuromodulatio...
25103 Rye Canyon Loop
Valencia, CA 91355
Founded in 2004
Key Executives for Bioness Inc.
Chief Executive Officer and President
Compensation as of Fiscal Year 2015.
Bioness Inc. Key Developments
Bioness Announces the Publication of Stimrouter Neuromodulation System Clinical Trial Results
Feb 1 16
Bioness Inc. announced the successful results from the company's 1-year clinical trial of the StimRouter Neuromodulation System. The results have been published in the January issue of Neuromodulation. The prospective, multi-center, randomized, double blinded, partial crossover study assessed safety and efficacy of the StimRouter Neuromodulation System for the treatment of patients with chronic pain of peripheral nerve origin. The StimRouter Treatment Group achieved primary endpoints of efficacy and safety and demonstrated a statistically significant (p<0.0001) improvement in pain reduction as compared to the control group. StimRouter received clearance from the Food and Drug Administration (FDA) last year and is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy. StimRouter is the only implantable neuromodulation device indicated and marketed to treat chronic pain of peripheral nerve origin. Unlike traditional pain management neuromodulation devices (e.g. spinal cord stimulators), StimRouter requires no trial lead, is minimally invasive and performed under local anesthesia. As a potential cost-effective alternative to injections, ongoing medication regimens and complex surgeries, StimRouter is enabling underserved patient populations to access neuromodulation technology to treat chronic pain.
Bioness Inc. Announces the Commercial Availability of StimRouter Neuromodulation System at International Neuromodulation Society World Congress
Jun 8 15
On June 8, 2015, at the International Neuromodulation Society 12th World Congress, Bioness Inc. announced the commercial availability of StimRouter, an implantable neuromodulation device to treat chronic, intractable pain of peripheral nerve origin as an adjunct to other modes of therapy. StimRouter received clearance from the United States Food and Drug Administration (FDA) in February and is the only implantable neuromodulation device indicated to treat chronic pain of peripheral nerve origin. StimRouter is cleared by the FDA to treat chronic pain of peripheral nerve origin. StimRouter is a minimally invasive neuromodulation medical device consisting of an implanted lead, external pulse transmitter (EPT) and conductive electrode, controlled by a small, hand-held wireless control unit. Electrical signals are transmitted transdermally from the EPT through the electrode, down the lead to the target nerve. Each system is programmed at the direction of the physician to meet patient requirements.
Bioness, Inc. Announces Strategic Business Partnership with the American Physical Therapy Association
May 14 15
Bioness Inc. announced that it has been named as a Strategic Business Partner by the American Physical Therapy Association (APTA). Bioness joins a select roster of other companies from the therapeutic device and medical device and services industries that work with APTA to promote evidence-based innovations and expand access to therapy. This partnership is a unique opportunity for Bioness to generate awareness and offer rehabilitation solutions to the 76,000 well-informed and influential current APTA members.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|